Concept · medicine
Neurofilament Light (NfL)
Follow Neurofilament Light (NfL) — see important new research and changes in evidence.Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published
Neurofilament light (NfL) is a structural axonal protein that leaks into blood and CSF when neurons are injured. In this library it appears as a plasma prognostic marker for later dementia and as a pharmacodynamic marker that falls during SOD1-ALS antisense treatment. Nearby fluid markers (for example CSF tau) answer related but not identical questions about early brain change.
Students meet NfL in two persuasive stories—years-ahead dementia risk and treatment response in ALS—that use the same analyte for different claims. The skill is stating which claim a study supports, what would falsify it, and what merely limits its scope.
Evidence
What the evidence shows
Drawn from 3 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Higher plasma NfL associates with higher later dementia risk in UK Biobank adults.
In UK Biobank adults with baseline plasma measures, higher NfL (and GFAP) associated with roughly doubled hazards of incident all-cause dementia over ~13 years, with protein elevations detectable up to about 15 years before diagnosis and useful incremental prediction alongside demographic risk scores.
- Does brain tau protein affect object memory in older adults?— different assay and compartment — CSF tau, not plasma NfL
- Real-world tofersen lowers neurofilaments in SOD1-ALS— different disease context — SOD1-ALS pharmacodynamics, not dementia prognosis
Study Role Design N Population Outcome Blood GFAP and NfL predict dementia years ahead Supports CohortUK Biobank prospective plasma GFAP/NfL with registry dementia follow-up N=48542 · 1,312 incident all-cause dementia over ~13 years UK Biobank adults with baseline Olink plasma GFAP and NfL Incident all-cause dementia / ADRD HRs and prediction AUC for GFAP and NfL Does brain tau protein affect object memory in older adults? Qualifiesdifferent assay and compartment — CSF tau, not plasma NfL OtherObservational CSF biomarker–fMRI association study; no assigned exposure N=21 · 21 cognitively unimpaired older adults analysed after spinal tap and mnemonic discrimination fMRI Cognitively unimpaired older adults Object mnemonic discrimination and hippocampal activation vs CSF tau Real-world tofersen lowers neurofilaments in SOD1-ALS Qualifiesdifferent disease context — SOD1-ALS pharmacodynamics, not dementia prognosis OtherProspective observational follow-up in Germany’s tofersen early-access program across ten MND-NET centres N=24 · SOD1-ALS patients treated March 2022–April 2023 Adults with SOD1-ALS in a German early-access programme ALSFRS-R progression and serum/CSF neurofilament change on tofersen In SOD1-ALS care, treatment can lower serum NfL as injury markers fall.
In German early-access SOD1-ALS care, tofersen treatment was accompanied by significant falls in serum NfL and CSF pNfH, with ALSFRS-R progression slower than patients’ pre-treatment slopes in the analyzed subset.
- Blood GFAP and NfL predict dementia years ahead— different question — long-horizon prognosis, not treatment monitoring
Study Role Design N Population Outcome Real-world tofersen lowers neurofilaments in SOD1-ALS Supports OtherProspective observational follow-up in Germany’s tofersen early-access program across ten MND-NET centres N=24 · SOD1-ALS patients treated March 2022–April 2023 Adults with SOD1-ALS in a German early-access programme ALSFRS-R progression and serum/CSF neurofilament change on tofersen Blood GFAP and NfL predict dementia years ahead Qualifiesdifferent question — long-horizon prognosis, not treatment monitoring CohortUK Biobank prospective plasma GFAP/NfL with registry dementia follow-up N=48542 · 1,312 incident all-cause dementia over ~13 years UK Biobank adults with baseline Olink plasma GFAP and NfL Incident all-cause dementia / ADRD HRs and prediction AUC for GFAP and NfL Higher CSF tau can track early memory and hippocampal activity changes before dementia.
In cognitively unimpaired older adults, higher CSF tau correlated with worse object mnemonic discrimination and greater right hippocampal task fMRI activity—evidence that a fluid neurodegeneration marker can track early functional brain changes before a dementia diagnosis.
- Blood GFAP and NfL predict dementia years ahead— different scale and analyte — biobank plasma NfL/GFAP, not CSF tau fMRI
Study Role Design N Population Outcome Does brain tau protein affect object memory in older adults? Supports OtherObservational CSF biomarker–fMRI association study; no assigned exposure N=21 · 21 cognitively unimpaired older adults analysed after spinal tap and mnemonic discrimination fMRI Cognitively unimpaired older adults Object mnemonic discrimination and hippocampal activation vs CSF tau Blood GFAP and NfL predict dementia years ahead Qualifiesdifferent scale and analyte — biobank plasma NfL/GFAP, not CSF tau fMRI CohortUK Biobank prospective plasma GFAP/NfL with registry dementia follow-up N=48542 · 1,312 incident all-cause dementia over ~13 years UK Biobank adults with baseline Olink plasma GFAP and NfL Incident all-cause dementia / ADRD HRs and prediction AUC for GFAP and NfL
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
UK Biobank treats baseline plasma NfL as a long-horizon prognostic marker for dementia in a general volunteer cohort. The tofersen series treats serial NfL/pNfH as a pharmacodynamic injury marker in SOD1-ALS. Both can be valid for their questions—the limit is not picking a winner, but not swapping prognostic and treatment-monitoring readings.
- Blood GFAP and NfL predict dementia years ahead
- Real-world tofersen lowers neurofilaments in SOD1-ALS
Study Role Design N Population Outcome Blood GFAP and NfL predict dementia years ahead Supports CohortUK Biobank prospective plasma GFAP/NfL with registry dementia follow-up N=48542 · 1,312 incident all-cause dementia over ~13 years UK Biobank adults with baseline Olink plasma GFAP and NfL Incident all-cause dementia / ADRD HRs and prediction AUC for GFAP and NfL Real-world tofersen lowers neurofilaments in SOD1-ALS Supports OtherProspective observational follow-up in Germany’s tofersen early-access program across ten MND-NET centres N=24 · SOD1-ALS patients treated March 2022–April 2023 Adults with SOD1-ALS in a German early-access programme ALSFRS-R progression and serum/CSF neurofilament change on tofersen Plasma GFAP/NfL at biobank scale forecast registry dementia years later; CSF tau in a small imaging sample tracks hippocampal hyperactivity and object memory. They share the idea that fluid markers can flag neurodegeneration early, while answering different assay, sample, and outcome questions.
- Blood GFAP and NfL predict dementia years ahead
- Does brain tau protein affect object memory in older adults?
Study Role Design N Population Outcome Blood GFAP and NfL predict dementia years ahead Supports CohortUK Biobank prospective plasma GFAP/NfL with registry dementia follow-up N=48542 · 1,312 incident all-cause dementia over ~13 years UK Biobank adults with baseline Olink plasma GFAP and NfL Incident all-cause dementia / ADRD HRs and prediction AUC for GFAP and NfL Does brain tau protein affect object memory in older adults? Supports OtherObservational CSF biomarker–fMRI association study; no assigned exposure N=21 · 21 cognitively unimpaired older adults analysed after spinal tap and mnemonic discrimination fMRI Cognitively unimpaired older adults Object mnemonic discrimination and hippocampal activation vs CSF tau
Common misconceptions
Elevated plasma NfL is a dementia-specific signal.
UK Biobank links NfL/GFAP to all-cause dementia risk but notes nonspecific elevation across neurological conditions; SOD1-ALS care also monitors NfL as axonal injury. A high value is not a specific Alzheimer’s label.
A fall in NfL during treatment is sufficient proof that the drug is clinically effective.
The German early-access series was open-label, small, and short, with recalled pre-baseline slopes—authors treat clinical benefit beyond biomarker change as uncertain and placebo effects as unexcluded.
CSF tau findings in 21 unimpaired adults generalize to plasma NfL screening programs.
That study is a small, cross-sectional CSF–fMRI correlation for object memory, not a plasma prognostic validation. It supports early fluid–brain coupling for tau, not biobank-scale NfL screening performance.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
A classmate says UK Biobank proves plasma NfL is a specific Alzheimer’s test. What position can you defend, what challenges it, and what would change your mind?
Defend: higher baseline plasma NfL associated with incident all-cause dementia (HR ~1.98 in model 3) years later, with incremental AUC when added to risk scores. Challenge specificity: the same paper calls GFAP/NfL nonspecific, and SOD1-ALS programs use NfL as an injury marker in a different disease. What would change the position: strong evidence that elevated NfL in community samples is driven almost entirely by AD pathology rather than other neurological injury—and prospective data separating AD from non-AD causes.
Why can falling NfL on tofersen support a pharmacodynamic claim without proving clinical efficacy?
Significant NfL/pNfH declines show the drug engages a neuronal-injury signal in SOD1-ALS early access. Efficacy for patients requires controlled evidence that functional outcomes improve beyond placebo/expectation; this series’ open-label design and uncertain clinical benefit beyond biomarkers leave that claim unsupported.
How should CSF tau–hippocampal findings qualify a plasma NfL dementia claim without challenging it?
They show another fluid marker can track early brain function before dementia diagnosis, which supports the broader idea of fluid neurodegeneration markers. They do not reverse the UK Biobank hazard ratios; they limit over-reading any one assay or compartment as the only early signal.
The studies
3 studies in this library bear on Neurofilament Light (NfL), ordered by citations.
- Blood GFAP and NfL predict dementia years ahead
In 48,542 UK Biobank participants followed ~13 years, elevated plasma GFAP and NfL preceded dementia up to 15 years and improved prediction beyond CAIDE/DRS risk scores (AUC up to ~0.89).
- Real-world tofersen lowers neurofilaments in SOD1-ALS
In 24 German early-access SOD1-ALS patients, tofersen slowed ALSFRS-R decline versus pre-treatment and cut serum NfL and CSF pNfH, but CSF pleocytosis was common.
- Does brain tau protein affect object memory in older adults?
Elevated levels of tau protein in the brain fluid of healthy older adults are linked to overactivity in the hippocampus and worse memory for distinguishing highly similar objects.
Learn alongside